Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials. Access and reimbursement.

W B Farrar1

  • 1Department of Surgery, Ohio State University College of Medicine, Columbus.

Cancer
|March 15, 1991
PubMed
Summary

Clinical trial participation remains low despite NCI outreach. Key barriers include physician concerns, perceived experimental therapy inferiority, and reimbursement issues from third-party payers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilization of genetic counseling services by surgical oncologists: education a must.

Clinical genetics·2006
Same author

Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer.

American journal of surgery·2001
Same author

Selective analysis of the sentinel node in breast cancer.

American journal of surgery·2001
Same author

NCCN Practice Guidelines for Breast Cancer.

Oncology (Williston Park, N.Y.)·2001
Same author

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients.

Journal of surgical oncology·2000

Area of Science:

  • Oncology
  • Clinical Research

Background:

  • Clinical trials are crucial in oncology, yet only 2.5% of US cancer patients participate annually.
  • The National Cancer Institute (NCI) has implemented promotional campaigns to improve access to clinical trials.

Purpose of the Study:

  • To identify factors hindering patient accrual in clinical oncology trials.
  • To address concerns regarding reimbursement for clinical research.

Main Methods:

  • Analysis of current clinical trial participation rates and NCI promotional strategies.
  • Identification of physician-related barriers and reimbursement challenges.

Main Results:

  • Low participation rates persist despite enhanced access initiatives.
  • Physician concerns (patient contact, experimental vs. standard therapy perception, time commitment) impede accrual.
  • Third-party payer reluctance to cover experimental therapies poses a significant threat to trial viability.

Conclusions:

  • Addressing physician concerns and ensuring adequate reimbursement are critical for increasing clinical trial participation.
  • Investment in clinical trials by payers is essential for long-term advancements in cancer care and cost reduction.

Related Experiment Videos